SLRX – salarius pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Form DEFA14A Salarius Pharmaceuticals
Form 8-K Salarius Pharmaceuticals For: Dec 19
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: HANISH ARNOLD C
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Marschel Peter Klaus
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Hibner Barbara Louise
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.